CD274 and neoplasm: Current research on the predictive biomarker of immune checkpoint inhibitors (ICIs) is focused on tumor characteristics namely the neoantigen burden calculated from somatic mutation,3, 4, 5 expression of PD‐L1,6 tumor microenvironment evaluated by infiltration of cytotoxic T cells,7, 8 and functional signatures related to cytotoxic activity.9